Kanisa Pharmaceuticals Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Liquidation

Kanisa Pharmaceuticals General Information

Description

Provider of oncology focused pharmaceutical services. The company is focused on developing new treatments for cancer with novel testing formats to stratify patients and predict likely responders to therapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 12264 El Camino Real
  • Suite 300
  • San Diego, CA 92130
  • United States
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • 12264 El Camino Real
  • Suite 300
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kanisa Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation 01-Jan-2018 Completed Out of Business
1. Early Stage VC (Series A) 27-Dec-2004 Completed Startup
To view Kanisa Pharmaceuticals’s complete valuation and funding history, request access »

Kanisa Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Kanisa Pharmaceuticals’s complete cap table history, request access »

Kanisa Pharmaceuticals Patents

Kanisa Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2006269498-A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins Inactive 06-Jul-2005
CA-2630087-A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins Inactive 06-Jul-2005
EP-1898957-A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins Inactive 06-Jul-2005
US-20070010485-A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins Inactive 06-Jul-2005
US-20070010486-A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins Inactive 06-Jul-2005 A61K47/40
To view Kanisa Pharmaceuticals’s complete patent history, request access »

Kanisa Pharmaceuticals FAQs

  • When was Kanisa Pharmaceuticals founded?

    Kanisa Pharmaceuticals was founded in 2004.

  • Where is Kanisa Pharmaceuticals headquartered?

    Kanisa Pharmaceuticals is headquartered in San Diego, CA.

  • What industry is Kanisa Pharmaceuticals in?

    Kanisa Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Kanisa Pharmaceuticals a private or public company?

    Kanisa Pharmaceuticals is a Private company.

  • What is Kanisa Pharmaceuticals’s current revenue?

    The current revenue for Kanisa Pharmaceuticals is .

  • How much funding has Kanisa Pharmaceuticals raised over time?

    Kanisa Pharmaceuticals has raised $24.8M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process